2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow STAR0602: new trials by email Literature Review of STAR0602 trials Research Report on STAR0602
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors STAR0602, Sacituzumab Govitecan (SG) - Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 50 | 2025-03-24 | 2025-09-24 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
Abdominal Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Epstein-Barr Virus Infections (1) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Genital Neoplasms, Female (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1)
Marengo Therapeutics, Inc. (2)
Canada (2) · United States (2) · France (1) · Spain (1)
2023 (1)